HS Design was selected as a supplier to a finalist for 2012 Medical Design Excellence Awards (MDEA). In the In Vitro Diagnostics category, HSD won for the Biomarker Strategies SnapPath 1000 instrument. The device, developed with funding support from the National Cancer Institute, is an automated live-tumor-cell processing device that enables next-generation biomarker tests, known as Functional Signaling Profiles (FSPs), to guide targeted drug therapy selection. Douglas P. Clark, MD, co-founder and Acting CEO for BioMarker Strategies remarked, “It is an honor to be recognized by the MDEA judges. The SnapPath™ platform responds to a growing need for new approaches to solid tumor testing that will reveal how a patient’s tumor will respond to targeted cancer therapies.” HS Design teamed with BioMarker Strategies and Sparton Medical for the design, engineering and manufacturing of the platform.